Overcoming challenges in the diagnosis and treatment of myasthenia gravis

Amelia Evoli Stampanoni-B, Raffaele Iorio, Emanuela Bartoccioni

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

5 Citazioni (Scopus)


In recent years, the discovery of new autoantigens and the use of sensitive assays have expanded the clinical spectrum of myasthenia gravis (MG). In particular, antibodies binding to clustered acetylcholine receptors and to the low-density lipoprotein receptor-related protein 4 have not only bridged a significant gap in diagnosis but also have relevant clinical implications. MG management includes different therapeutic options, from symptomatic agents as the only therapy in mildly affected cases to combined long-term immunosuppression and thymectomy in patients with severe disabling disease. MG biological diversity can influence the response to therapies and should be taken into account when planning treatment. Biologic agents are promising, though their use is currently limited to patients with refractory disease.
Lingua originaleEnglish
pagine (da-a)1-12
Numero di pagine12
RivistaExpert Review of Clinical Immunology
Stato di pubblicazionePubblicato - 2015


  • AChR
  • Lrp4
  • MuSK
  • clustered-AChR
  • immunosuppressants
  • myasthenia gravis
  • thymectomy


Entra nei temi di ricerca di 'Overcoming challenges in the diagnosis and treatment of myasthenia gravis'. Insieme formano una fingerprint unica.

Cita questo